BLOG

GEN

Tumor-Agnostic Therapy for Anti-PD-1 Nonresponders

OncoSec Medical’s Tavo, a DNA-based interleukin-12 immunotherapy that is delivered to tumors via electroporation, is currently in Phase II trials